Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

fludarabine phosphate 2fludarabine 2Tacrolimus 2Specimen Handling 2Mycophenolic Acid 2Cyclophosphamide 2Busulfan 2Biopsy 2venetoclax 1veliparib 1tagraxofusp 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Topotecan 1Thiotepa 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Injections 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Decitabine 1Cytarabine 1Cyclosporine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myelodysplastic-Myeloproliferative Diseases × Idarubicin × Clear all
NCT06034470 2026-05-07

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡